Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Ani Pharmaceuticals (ANIP) over the last 12 years, with Q3 2025 value amounting to $18.8 million.

  • Ani Pharmaceuticals' Deferred Taxes rose 43643.52% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year increase of 5562.1%. This contributed to the annual value of -$21.9 million for FY2024, which is 8665.25% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Deferred Taxes of $18.8 million as of Q3 2025, which was up 43643.52% from -$3.5 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Deferred Taxes registered a high of $18.8 million during Q3 2025, and its lowest value of -$17.5 million during Q4 2024.
  • In the last 5 years, Ani Pharmaceuticals' Deferred Taxes had a median value of -$3.3 million in 2023 and averaged -$2.8 million.
  • In the last 5 years, Ani Pharmaceuticals' Deferred Taxes plummeted by 257526.88% in 2022 and then surged by 43643.52% in 2025.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Deferred Taxes stood at -$8.1 million in 2021, then surged by 79.91% to -$1.6 million in 2022, then plummeted by 413.6% to -$8.3 million in 2023, then plummeted by 110.04% to -$17.5 million in 2024, then soared by 207.24% to $18.8 million in 2025.
  • Its Deferred Taxes stands at $18.8 million for Q3 2025, versus -$3.5 million for Q2 2025 and -$3.4 million for Q1 2025.